Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.37B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.04M
Average 0.08M
NBTX Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Nanobiotix S.A.NASDAQ: NBTX
Gross Margin · Q4 FY2025 · quarter ended Dec 2025
Gross margin holds steady near 100.0%
Gross margin was 100.0% in Q4 FY2025, up 0.0 pp from a year earlier. Over 3 fiscal years it widened by 0.0 pp.
Context
- Gross margin widened in 0 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 100.0%
- Year-over-year change
- +0.0pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.0% | +0.0pp |
| FY2024 | 2024-12-31 | 100.0% | +0.0pp |
| FY2023 | 2023-12-31 | 100.0% | +0.0pp |
| FY2022 | 2022-12-31 | 100.0% | +0.0pp |
| FY2021 | 2021-12-31 | 100.0% | — |
Gross Margin vs competitors
How NBTX compares with its peers on the latest reported figures
- NBTX's FY2025 gross margin of 100.0% is the highest of the 6 companies compared; the peer median is 96.7%.
- Its year-over-year change of +0.0 pp is the 3rd highest of 5, against a peer median of +0.9 pp.
- Over three fiscal years its change of +0.0 pp compares with a peer median of -1.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 100.0% | +0.0 pp | +0.0 pp | |
| FY2025 | 99.5% | — | — | |
| LTM Mar 2026 | 98.0% | -0.0 pp | — | |
| LTM Sep 2026 | 96.7% | +1.9 pp | -0.7 pp | |
| LTM Mar 2026 | 94.7% | -5.0 pp | — | |
| LTM Mar 2026 | 74.5% | +2.1 pp | -1.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NBTX) | 96.7% | +0.9 pp | -1.0 pp | |
Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 30.38M | 32.64M | 38.4M | 40.54M | 23.12M |
| Selling, General & Admin | 19.43M | 17.86M | 22.05M | 20.53M | 20.22M |
| Operating Expenses | 55.23M | 51.48M | 62.99M | 61.2M | 40.46M |
| Depreciation & Amortization | 1.56M | 1.5M | 551K | 592K | 1.5M |
| EBITDA | (45.61M) | (44.22M) | (23.69M) | (67.67M) | (12.07M) |
| EBITDA Margin | -1722.9% | -925.8% | -65.4% | 941.1% | -40.7% |
| Operating Income | (52.58M) | (46.7M) | (26.78M) | (68.39M) | (10.82M) |
| Operating Margin | -1986.4% | -977.8% | -74.0% | 951.2% | -36.5% |
| Interest Income | 0 | 256K | 1.22M | 2.63M | 985K |
| Interest Expense | 699.49K | 5.84M | 7.98M | 8.09M | 10.4M |
| Other Income / Expenses | 5.58M | (10.33M) | (12.8M) | 361K | (13.14M) |
| Income Before Tax | (47M) | (57.03M) | (39.58M) | (68.03M) | (23.96M) |
| Pre-Tax Margin | -1775.5% | -1194.1% | -109.3% | 946.2% | -80.8% |
| Income Tax Expense | 5K | 10K | 120K | 101K | 3K |
| Net Income | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Net Margin | -1775.7% | -1194.3% | -109.6% | 947.6% | -80.8% |
| EPS (Basic) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| EPS (Diluted) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| Weighted Avg Shares | 34.73M | 34.85M | 36.76M | 47.27M | 47.82M |
| Weighted Avg Shares (Diluted) | 34.73M | 34.85M | 36.93M | 47.27M | 47.82M |
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$26.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.